The call highlights significant progress in Vir Biotechnology's hepatitis delta and oncology programs, alongside a strong financial position and cost efficiency improvements. However, the company continues to operate at a loss and has significant cash consumption. The positive developments in clinical programs and financial management contribute to a balanced outlook.

Company Guidance -

Q3 2025

During Vir Biotechnology's second quarter 2025 call, the company provided guidance on several key metrics. They highlighted the enrollment of the first patients in both ECLIPSE 2 and ECLIPSE 3, advancing the ECLIPSE registrational program for hepatitis delta. The program aims to address approximately 7 million active viremic HDV RNA-positive patients globally, including 61,000 in the U.S. They also initiated a Phase I study for VIR-5525, their third clinical stage T cell engager program. Financially, Vir reported $892 million in cash and equivalents, with a cash runway extending into mid-2027. They recorded a net loss of $111 million for the quarter, slightly improved from the $138.4 million loss in the same period of 2024. The call emphasized the company's focus on advancing key programs and exploring commercialization partnerships.

Advancements in Hepatitis Delta Program

Significant progress in the ECLIPSE registrational program for hepatitis delta with the enrollment of first patients in ECLIPSE 2 and ECLIPSE 3, alongside ECLIPSE 1. All three studies are actively recruiting globally.

Oncology Program Developments

Initiated Phase I study for VIR-5525, an EGFR-targeted T cell engager, marking it the third clinical-stage T cell engager program. Progress in existing programs with VIR-5818 and VIR-5500 advancing in their Phase I studies.

Financial Strength and Cash Runway

Strong financial position with approximately $892 million in cash, cash equivalents, and investments, providing a cash runway extending into mid-2027.

Cost Efficiency Improvements

Reduced R&D and SG&A expenses, with a year-over-year reduction in operating expenses by $42.1 million, reflecting cost savings from restructuring.

Vir Biotechnology (VIR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VIR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.84 / -	-1.56	―	―	―
Aug 06, 2025	2025 (Q2)	-0.72 / -0.80	-1.02	21.57% (+0.22)
May 07, 2025	2025 (Q1)	-0.84 / -0.88	-0.48	-83.33% (-0.40)	―
Feb 26, 2025	2024 (Q4)	-0.87 / -0.76	-0.86	11.63% (+0.10)
Oct 31, 2024	2024 (Q3)	-1.05 / -1.56	-1.22	-27.87% (-0.34)
Aug 01, 2024	2024 (Q2)	-0.90 / -1.02	-1.45	29.66% (+0.43)
May 02, 2024	2024 (Q1)	-1.05 / -0.48	-1.06	54.72% (+0.58)
Feb 22, 2024	2023 (Q4)	-1.01 / -0.86	-0.76	-13.16% (-0.10)
Nov 02, 2023	2023 (Q3)	-1.21 / -1.22	1.3	-193.85% (-2.52)
Aug 03, 2023	2023 (Q2)	-1.20 / -1.45	-0.58	-150.00% (-0.87)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VIR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$5.08	$4.35	-14.37%
May 07, 2025	$5.61	$5.41	-3.57%
Feb 26, 2025	$9.20	$8.11	-11.85%
Oct 31, 2024	$7.49	$9.26	+23.63%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Vir Biotechnology, Inc. (VIR) report earnings?

Vir Biotechnology, Inc. (VIR) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Vir Biotechnology, Inc. (VIR) earnings time?

Vir Biotechnology, Inc. (VIR) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VIR EPS forecast?

VIR EPS forecast for the fiscal quarter 2025 (Q3) is -0.84.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing